Lv1
30 积分 2026-08-21 加入
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
3小时前
已完结
Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary
3小时前
已完结
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
4小时前
已完结
皖公网安备34019202002308
